Nevertheless, the activity empowerment was quite variable: in the case of lysozyme + colistin, the ranges of fold-reduction in viability were 5.8–821.3 for bacteremia, and 6.9–145.5 for CF isolates. The gene discussed is LYZ; the disease is cystic fibrosis.